News | May 13, 2025
Morepen Board proposed dividend after 23 years
Scores highest PAT of Rs. 118 crore in FY25
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Gelhaus has a proven track record of driving business growth
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
